AriBio to present AR1001 phase 3 results at CTAD 2026 in Boston Korea Biomedical Review 01:09 Wed, 22 Jul
AriBio’s AR1005 shows early efficacy signals in Lewy body dementia phase 2a trial Korea Biomedical Review 02:13 Thu, 16 Jul
AriBio receives remaining $50 mil. payment from Fosun for oral Alzheimer’s drug Korea Biomedical Review 07:03 Mon, 13 Jul
Fosun Pharma to invest $27.5 mil. in AriBio after AR1001 licensing deal Korea Biomedical Review 05:20 Fri, 03 Jul
AriBio signs 42.5 billion won strategic equity investment contract with Fosun Pharma Asia Today 01:41 Fri, 03 Jul
AriBio completes main phase 3 dosing for oral Alzheimer's drug AR1001, topline data due this fall Korea Biomedical Review 05:49 Mon, 29 Jun
[BIO USA 2026] AriBio broadens dementia pipeline strategy after Fosun deal: AriBio USA chief Korea Biomedical Review 01:52 Thu, 25 Jun
